Related Articles
Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first‑line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases
Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines